GLP-1 RA: The initiation of GLP-1 receptor agonist therapy should be based on obesity levels(BMI≥24Kg/m2) and a personal history of ASCVD. The recommendation is that this therapy be initiated promptly rather than being based on blood glucose levels (89).. SGLT2i: may be considered as agents with potential weight-loss benefit. Treatment selection should primarily aim for effective body-weight control (90). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.